X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Ranbaxy vs Dr. Reddy's: Which one is better? - III - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Apr 8, 2011

    Ranbaxy vs Dr. Reddy's: Which one is better? - III

    We completed two articles where we compared Ranbaxy and Dr Reddy's on their business profiles, revenue segments and revenue growth among others. In this final article we will compare the balance sheet ratios and the price performance for the two companies.

    The charts for the return on capital employed (ROCE) and debt to equity ratio for both companies are shown below. ROCE tells us the profit earned by the companies on the total invested capital (shareholders money and loans) while debt to equity ratio gives us the sense of proportion of debt compared to that of shareholder's funds (equity).

    From the charts, we can see that Dr Reddy's is a clear winner when compared to Ranbaxy in terms of ROCE as well as debt to equity ratio. The reason for this is not just Dr Reddy's good performance but also Ranbaxy's below average performance.

    Dr Reddy's had excellent opportunities to sell a few products having the exclusivity period in the last few years in the US market. This helped in boosting its revenue and therefore returns. But Ranbaxy was not as successful as Dr Reddy's in converting - its exclusivity opportunities. For example, Sumatriptan, a generic version of Imitrex was launched by Dr Reddy's but not by Ranbaxy because the latter was embroiled in issues with the US FDA. The loss for Ranbaxy was a gain for Dr Reddy's.

    Having said this, Dr Reddy's shareholder's equity decreased in FY08 as it had written off its entire goodwill from the Betapharm acquisition. This led to a significant increase in ROCE in FY09 onwards (due to decrease in capital employed). The company's total debt position is now quite reasonable as the total debt to equity ratio stood at 0.4 for FY10. The management has also guided to a RoCE of 25% for FY13 and we can see the ROCE inching upwards.

    As suggested above Ranbaxy was not as successful as Dr Reddy's with its exclusivity opportunities in the US market in the last few years even though it has been successful in baggin quite a few of them. This was largely due to the US FDA finding fault with the manufacturing standards at two of its plants at Dewas and Poanta Sahib. The company had to shut down these plants and therefore the sales of 30 of its products stopped in the US market. This had a huge impact on its profits which in turn impacted the ROCE adversely.

    On the debt front, in FY06, the company raised significant amount through foreign currency convertible bonds (FCCB). This increased the debt to equity ratio considerably. After the Daiichi Sankyo taking over the management control, continuous efforts were put to reduce debt. This is evident as the debt to equity ratio has decreased over last two years. At the start of CY11, the company retired its FCCB loan by paying it off. This will further reduce the debt equity ratio for Ranbaxy.

    Price performance for the two companies

    The chart above shows how the value of Rs 100 invested in Jan 2007 changed over time. As expected, Dr Reddy's price performance has been much better than that of Ranbaxy. Over these 4 years, Ranbaxy's price increased by 13% while Dr Reddy's increased by more than 100%.

    We can conclude that in the past few years, Dr Reddy's has done phenomenally well as compared to Ranbaxy. The fact that Dr.Reddy's management is more proactive and stresses on good corporate governance also gives it the edge over Ranbaxy. While the future prospects for Dr.Reddy's look good, a question mark still remains over the performance of its German subsidiary Betapharm.

    For Ranbaxy, after Daiichi Sankyo took it over, the financial health of the former has improved substantially. The synergetic benefits coming from Daiichi Sankyo acquiring Ranbaxy should start showing up. Ranbaxy has some exclusivity opportunities lined up (Lipitir and Nexium). But a lot depends on the verdict given by the US FDA. The withdrawal of the USFDA ban on two of Ranbaxy's facilities will indeed do wonders for the company.

    Ranbaxy vs Dr Reddy's Which one is better? - Series - Previous article | All Articles

     

     

    Equitymaster requests your view! Post a comment on "Ranbaxy vs Dr. Reddy's: Which one is better? - III". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 18, 2017 02:49 PM

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS